Wiendl, Heinz and Gold, Ralf and Berger, Thomas and Derfuss, Tobias and Linker, Ralf and Maurer, Mathias and Aktas, Orhan and Baum, Karl and Berghoff, Martin and Bittner, Stefan and Chan, Andrew and Czaplinski, Adam and Deisenhammer, Florian and Di Pauli, Franziska and Du Pasquier, Renaud and Enzinger, Christian and Fertl, Elisabeth and Gass, Achim and Gehring, Klaus and Gobbi, Claudio and Goebels, Norbert and Guger, Michael and Haghikia, Aiden and Hartung, Hans-Peter and Heidenreich, Fedor and Hoffmann, Olaf and Kallmann, Boris and Kleinschnitz, Christoph and Klotz, Luisa and Leussink, Verena I. and Leutmezer, Fritz and Limmroth, Volker and Lunemann, Jan D. and Lutterotti, Andreas and Meuth, Sven G. and Meyding-Lamade, Uta and Platten, Michael and Rieckmann, Peter and Schmidt, Stephan and Tumani, Hayrettin and Weber, Frank and Weber, Martin S. and Zettl, Uwe K. and Ziemssen, Tjalf and Zipp, Frauke (2021) Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 14. ISSN 1756-2856, 1756-2864
Full text not available from this repository. (Request a copy)Abstract
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; 1ST DEMYELINATING EVENT; 5-YEAR FOLLOW-UP; INTERFERON BETA-1A; INTRAMUSCULAR INTERFERON; PHARMACOLOGICAL-TREATMENT; ECTRIMS/EAN GUIDELINE; CLINICALLY DEFINITE; ORAL CLADRIBINE; disease-modifying therapy; guideline; multiple sclerosis; treatment recommendation |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 30 Nov 2022 14:06 |
| Last Modified: | 30 Nov 2022 14:06 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48206 |
Actions (login required)
 |
View Item |
